Celldex Therapeutics Inc. (CLDX) was one of the Russell 2000's biggest losers for Thursday February 18 as the stock slid 5.67% to $7.07, a loss of $-0.425 per share. Starting at an opening price of $7.50 a share, the stock traded between $6.73 and $7.58 over the course of the trading day. Volume was 2.48 million shares over 14,852 trades, against an average daily volume of 2.49 million shares and a total float of 98.65 million.
The losses send Celldex Therapeutics Inc. down to a market cap of $696.93 million. In the last year, Celldex Therapeutics Inc. has traded between $32.82 and $6.25, and its 50-day SMA is currently $12.01 and 200-day SMA is $17.57.
Celldex Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the development, manufacturing and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Celldex Therapeutics Inc. is based out of Hampton, NJ and has some 161 employees. Its CEO is Anthony S. Marucci.
For a complete fundamental analysis analysis of Celldex Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for CLDX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.